JPRN-UMIN000042461已完成未知
An International, Stepped-Wedge, Cluster-Randomized Trial Investigating the 0/1-hour Algorithm in Suspected Acute Coronary Syndrome in Asia:The rational of the DROP-Asian ACS study - DROP-Asian ACS
Juntendo University Nerima Hospital Department of Cardiovascular and biology0 个研究点目标入组 3,728 人开始时间: 2021年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3,728
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 89years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •ST elevation myocardial infarction On chronic hemodialysis A clear alternative case for the symptoms othe than ACS Symptomatic patients with atrioventricular nodal re-entrant tachycardia demonstrate ST-segment depressions and relevant troponin kinetics. Because it is impossible to make a different diagnosis with type 1 MI, type 2 MI, MI with non-obstructive coronary arteries, or acute myocardial injury, we decided not to include these patients. Acute heart failure due to already known non-coronary heart disease without suspected ACS. Congestive heart failure with hypoxemia Infection Cariogenic shock Dementia (Mini Mental State Examination; MMSE less than 20). Confirmed primary pulmonary disease without suspected ACS. Traumatic chest pain with preceded thorax injury without suspected ACS. Inability or unwillingness to provide informed consent
研究者
相似试验
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)EUCTR2006-006748-76-BGPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK219
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/AEUCTR2006-006748-76-GRPfizer Ltd. Ramsgate Road, Sandwich, Kent, UK284
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH).MedDRA version: 8.1Level: LLTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-006748-76-NLPfizer Ltd. Ramsgate Road, Sandwich, Kent, UK284
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)EUCTR2006-006748-76-DKPfizer Ltd, Ramsgate Road, Sandwich, Kent UK219
进行中（未招募）
1 期
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)EUCTR2006-006748-76-GBPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK219